Recent news reports and statistical information indicate that this year the incidence rate for seasonal influenza (flu) is already high and is widely impacting communities across the nation. The good news is that the flu immunization prepared for the 2012-2013 flu season appears to be very well matched to those flu strains occurring across the country; therefore, preventative measures such as obtaining a flu vaccine may be helpful in preventing the contraction of the flu.
Read News ArticleCategory: Latest News
MSAA’s Mobile Phone App Launches in the Android Marketplace
My MS Manager™, the first-of-its-kind mobile phone application developed to help individuals better manage their MS, is now available on the Android platform. Since its launch in the Apple App Store in June of 2011, My MS Manager has been downloaded more than 9,000 times, with users entering data about their MS on various Apple mobile products.
Read News ArticleEmergency and Assistive Services in Response to Hurricane Sandy
The impact of Hurricane Sandy to the residents of the mid-Atlantic, Northeastern, and Midwestern United States has been devastating. MSAA’s staff is deeply saddened by the tragic loss of life as well as the destruction of personal possessions, homes, and businesses, caused by this storm.
Read News ArticleVaccination Safety
Recent studies continue to aff …
Read News ArticleAubagio® (Oral Teriflunomide) Receives FDA Approval
Updated: September 17, 2012 On September 12, 2012, Sanofi and its subsidiary Genzyme announced that the United States Food and Drug Administration (FDA) had approved their new drug, Aubagio® (oral teriflunomide), for relapsing forms of multiple sclerosis (MS). The FDA had accepted their New Drug Application (NDA) in October, 2011.
Read News ArticleMSAA Receives APEX Award for Publication Excellence
MSAA is proud to announce that a 2012 APEX Award for Publication Excellence has been given to our online video webinar, "How to S.E.A.R.C.H..™ for the Right MS Therapy for You!" This is the first APEX Award MSAA has received in the category of webinars and the eighth APEX Award received overall. This year’s APEX award competition drew approximately 3,400 entries across a range of 11 categories.
Read News ArticleHighlights from The Consortium of Multiple Sclerosis Centers Annual Meeting, Held in San Diego (May 31 – June 4, 2012)
The Consortium of Multiple Sclerosis Centers (CMSC) annual meeting provides a unique opportunity for MS professionals to come together in an interdisciplinary setting to discuss all aspects of MS care. Attendees include physicians, nurses, physical and occupational therapists, psychologists, social workers, and other MS professionals. Topics are wide-ranging, from the latest advances in research and symptom management, to practical workshops designed to improve hands-on care.
Read News ArticleSupreme Court Upholds Affordable Care Act
On June 28, 2012 a historic decision was made by the United States Supreme Court to uphold the Affordable Care Act (ACA). The ACA was originally approved by Congress and was then signed into law on March 23, 2010. The law was designed to make many changes to the way the healthcare and insurance systems work in the United States, with most of the scheduled changes requested to be implemented within a four-year period, or by the end of 2014.
Read News ArticleMultiple Sclerosis Association of America’s MRI Institute Marks 10 Years of Helping Individuals with Multiple Sclerosis Obtain MRIs
The Multiple Sclerosis Association of America (MSAA) is proud to mark the 10-year anniversary of one of its most sought after programs – the MRI Institute. This program is designed to help people who have been diagnosed with multiple sclerosis (MS) and lack health insurance coverage, acquire an MRI scan. The Institute has been supported by the pharmaceutical companies EMD Serono, Inc. and Pfizer Inc since 2002. During that time, the Institute has helped over 7,500 individuals who have MS and could not otherwise afford an MRI to monitor their multiple sclerosis.
Read News ArticleHighlights from The American Academy of Neurology’s Annual Meeting
This year’s American Academy of Neurology (AAN) meeting was especially exciting for multiple sclerosis (MS) clinicians and researchers. Results were presented from clinical trials that have been ongoing for the past three-to-four years, many of which focus on the "new generation" of oral drugs for managing MS progression. Studies have looked at the effectiveness and safety of the new agents, particularly as compared to the standard injectible drugs that became available starting in the early 1990’s. Data on these new agents have been released gradually as the studies progressed through the clinical trials process, and anticipation of the details from completed studies has been building.
Read News Article